Brief: Emmaus Life Sciences Presents Positive Transfusion Data From A Post-HOC Analysis Of Its Phase 3 Clinical Study Of Endari In Patients With Sickle Cell Disease
14/12/2021 14:04
Dec 14 (Reuters) - Emmaus Life Sciences Inc EMMA.PK :
* EMMAUS LIFE SCIENCES PRESENTS POSITIVE TRANSFUSION DATA
FROM A
POST-HOC ANALYSIS OF ITS PHASE 3 CLINICAL STUDY OF ENDARI® IN
PATIENTS WITH SICKLE CELL DISEASE
Source text for Eikon: ID:nPn1LWFx0a
Further company coverage: EMMA.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Emmaus Life Sciences
See all newsEmmaus Life Sciences Q2 revenue soars on licensing deal
Emmaus Life Sciences Q1 revenue falls driven by lower sales in U.S.
Brief: Emmaus Life Sciences Enters License And Distribution Agreement With Neoimmunetech
Emmaus Life Sciences Q3 revenue falls 38%, swings to loss
Brief: Emmaus Life Sciences CFO Yasushi Nagasaki Resigns